[Therapeutic effect of a new human immunoglobulin SM-4300 on the severe infections in surgical patients].
A newly developed human immunoglobulin preparation for intravenous use, SM-4300, had been studied in the field of surgery. SM-4300 was administered to 2 patients with severe infection in the combined use with antibiotics. SM-4300 was considered to be a safe and effectively useful drug. One case with suspicious of septicaemia was excellent response to SM-4300, at a dosage of 2.5 g/day x 3, and another case with postoperative diffuse peritonitis was not effective at a dosage of 5.0 g/day x 1. No objective and subjective side effect and abnormal laboratory finding was observed in 2 cases.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001424:Bacterial Infections / Q000628:therapy*; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000628:therapy; D011183:Postoperative Complications / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; C044640:SM-4300